Discover
SLNO
Soleno Therapeutics, Inc.
53.01
2 x 38.15
2 x 67.82
bid
ask
+
0.00
0.00%
2 @ 04:00 PM
52.99 -0.02 (0.04%)
| Ytd | 14.49% | |
| 1y | -29.33% |
52.98
day range
53.01
29.43
52 week range
90.32
| Open | 52.98 | Prev Close | 53.01 | Low | 52.98 | High | 53.01 | Mkt Cap | 2.76B |
| Vol | 4.97M | Avg Vol | 3.62M | EPS | 1.93 | P/E | 27.47 | Forward P/E | -23.35 |
| Beta | -2.22 | Short Ratio | 1.01 | Inst. Own | 111.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 45.78 | 200-d Avg | 51.16 | 1yr Est | 53.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-06 | 2026-03 | 0.73 | N/A | N/A | N/A |
| 2026-02-25 | 2025-12 | 0.64 | 0.8 | 0.16 | 25.00% |
| 2025-11-04 | 2025-09 | 0 | 0.47 | N/A | N/A |
| 2025-08-06 | 2025-06 | 0 | N/A | 0.44 | 83.02% |
| 2025-05-07 | 2025-03 | 0 | N/A | 0.19 | 16.67% |
| 2025-02-27 | 2024-12 | 0 | N/A | -0.64 | -101.59% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-04-17 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| 2026-04-08 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| 2026-04-07 | TD Cowen | Downgrade | Buy | Hold |
| 2026-04-07 | Wolfe Research | Downgrade | Outperform | Peer Perform |
| 2026-04-06 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
| 2026-03-18 | Oppenheimer | Upgrade | Outperform | Outperform |
Profile
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. As of May 18, 2026, Soleno Therapeutics, Inc. operates as a subsidiary of Neurocrine Biosciences, Inc.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-01-20 | ANISH BHATNAGAR | Chief Executive Officer | 583.66K | Stock Award(Grant) |
| 2026-03-01 | FULK JENNIFER | Chief Financial Officer | 39.20K | Conversion of Exercise of derivative security |
| 2026-01-20 | HIRANO PATRICIA C | Officer | 22.70K | Stock Award(Grant) |
| 2026-03-26 | HUANG MICHAEL F | Officer | 39.82K | Sale |
| 2026-01-20 | JOSHI MANHER | Officer | 20.17K | Stock Award(Grant) |
| 2026-01-20 | MACKANESS JAMES H | Chief Financial Officer | 131.76K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Janus Henderson Group PLC | 7.10M | 376.34M | 13.62% |
| 2026-03-30 | FMR, LLC | 5.79M | 306.84M | 11.11% |
| 2026-03-30 | Wellington Management Group, LLP | 4.43M | 234.66M | 8.49% |
| 2026-03-30 | Blackrock Inc. | 3.74M | 198.40M | 7.18% |
| 2026-03-30 | State Street Corporation | 2.68M | 142.11M | 5.14% |
| 2026-03-30 | Avoro Capital Advisors LLC | 2.30M | 121.92M | 4.41% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-01-30 | VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2.42M | 128.14M | 4.64% |
| 2026-03-30 | Fidelity Rutland Square TRT II-Strategic Advisers U.S. Total Stock Fd. | 2.05M | 108.69M | 3.93% |
| 2026-04-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.67M | 88.63M | 3.21% |
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.63M | 86.33M | 3.12% |
| 2025-12-30 | T. Rowe Price All-Cap Opportunities Fd., Inc.-T. Rowe Price All-Cap Op | 1.32M | 69.99M | 2.53% |
| 2026-03-30 | iShares Trust-iShares Russell 2000 ETF | 1.22M | 64.62M | 2.34% |
Split
| Split | Date |
|---|---|
| 1 : 15 | 2022-08-26 |
| 1 : 5 | 2017-10-06 |